EANS-Adhoc: LifeWatch receives the "Indian Certificate" for its LifeWatch V health smartphone (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

other/New Products/LifeWatch AG
19.12.2012

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss
Exchange: LIFE), the leading wireless remote cardiac and medical
patient monitoring service provider in the U.S., today reports the
receipt of the No Objection Certificate from the Central Drugs
Standard Control Organization of the Indian Ministry of Health &
Family Welfare. LifeWatch may now export and sell the LifeWatch V
smartphone across India.

You will find a PDF-version of this press release at the end of this
message.

Shortly after being awarded the CE mark for the LifeWatch V health
smartphone platform, LifeWatch can today report another milestone for
its state-of-the-art device dedicated to health and wellness
conscious consumers. The Central Drugs and Standard Control
Organization of the Indian Ministry of Health & Family Welfare in New
Dehli has granted the No Objection Certificate ("NOC") for the
LifeWatch V health smartphone. This certificate allows LifeWatch to
export and sell the device across India.

The LifeWatch V is a fully featured state-of-the-art smartphone that
allows patients and health- and wellbeing-conscious consumers to
self-operate a wide range of embedded medical sensors,
wellness-related applications, cloud-based services and 24/7 call
center support. By using the barely visible sensors on the phone's
frame, users can track, capture, collect and analyze their health
measurements anywhere anytime. The sensors include ECG, body
temperature, blood glucose, heart rate, blood oxygen saturation, body
fat percentage and stress analysis measurement. All of the collected
data can be retrieved from the cloud for a follow-up. Users can take
corrective action, plan diets and activities, securely share the
information with a health provider or family member, trend and
analyze the data and more. Patients may also program the LifeWatch V
to remind them of their drug type, dose and intake time.

The LifeWatch V smartphone is an important milestone on the Company's
way towards more diversification into new service areas such as the
consumer and wellness markets and into new geographies. With the NOC
certificate, LifeWatch can enter the Indian marketplace which is
considered one of the most important future healthcare markets in the
world.

"Our receipt of the NOC is another important step in the go-to-market
strategy of the LifeWatch V smartphone, and closely follows our
announcement of being rewarded the CE mark in the beginning of
December 2012", stated Dr. Yacov Geva, Chairman of LifeWatch AG.
"This latest approval demonstrates again our capacity to develop and
manufacture devices that meet commercial regulatory requirements not
only in the U.S. but also in important emerging markets like India".

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
AG has operative subsidiaries in the United States, in Switzerland
and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a
leading US-based provider of cardiac monitoring services and home
sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch
Technologies Ltd., based in Israel, is a leading developer and
manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical
sensors and apps that uses a cloud-based service platform. For
additional information, please visit {www.lifewatch.com}[HYPERLINK:
http://www.lifewatch.com].

Sign-up for customized email alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/IPI4rsuU

Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/IPI4rsuU

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English